Flmodafinil

Flmodafinil (also known as Lauflumide, CRL-40,940; CAS 90212-80-9; molecular formula C15H13F2NO2S; molecular weight 309.33) is a bisfluoro-substituted analog of modafinil developed in the 1980s at Laboratoire Lafon as part of an exploratory series investigating ring-fluorinated modafinil derivatives. The two fluorine atoms are positioned para to the diphenylmethyl carbon (one on each ring), an arrangement that increases lipophilicity, slows hepatic metabolism, and reportedly enhances dopamine transporter binding affinity by approximately 4-fold relative to modafinil in displacement assays. Published preclinical work is limited; the compound did not advance to clinical development under the Lafon program. The research-grade literature reports plasma half-life on the order of 14 to 18 hours in rodents and a dose-response curve shifted leftward relative to modafinil (effective wakefulness doses approximately one-third to one-half of equivalent modafinil doses). The compound is not approved by any regulatory authority for any indication. There is no human clinical trial record. Anecdotal user reports describe a subjective profile similar to modafinil with longer duration and somewhat greater stimulant character, consistent with the leftward DAT-affinity shift. Long-term safety data are absent. Flmodafinil should be regarded as an experimental research chemical with a sparse evidence base; the bisfluoro substitution introduces metabolic uncertainties (the fluorinated diphenylmethyl scaffold is metabolically resistant, potentially leading to accumulation with chronic dosing) and the absence of clinical pharmacology limits any confident interpretation.